Fact CheckerSign in

NCT06178341Completed

Effects of the Kata® Inhalations-App on Inhaler Handling Errors, Adherence, and Asthma Control in Patients With Asthma.

Randomized, Controlled Study to Evaluate the Effectiveness of the Kata® Inhalations-App in Reducing Critical and Non-critical Handling Errors and Improving Adherence to Prescribed Drug Inhalation Therapy and Asthma Control in Adult Patients With Asthma

Source: ClinicalTrials.gov · Last updated 17 Jun 2025

Brief summary (registry, in English)

The Kata® App is a digital therapy assistant for patients with asthma who need to inhale their therapy. Kata features inhalation trainers that shows patients in a simple and understandable way how to improve their inhalation maneuver so that the drug reaches the lungs efficiently. The Kata® App aims to reduce inhalation errors and ensures that inhaled drugs are used as approved and prescribed. Kata has different trainers for different inhalation devices. This study investigates the possible positive effects of the Kata® Inhalation App. The main goal of the study is to: 1. investigate the effect of using the Kata® App on adherence for inhaled drugs in adult asthma patients. It consists of two parts: the correct use of the inhalers; and compliance with the therapy, or how much the patient follows the therapy plan as prescribed. 2. investigate the effect of using the Kata® App on asthma symptoms and asthma control, as measured by the Asthma Control Test (ACT) questionnaire. In addition, asthma-related quality of life, lung function, and ease of use of the app will be assessed during the study. This multicenter study follows a randomized, controlled, parallel-group, adaptive two-stage design. The study includes two different groups: an intervention and a control group. At the beginning of the study, each patient is randomly assigned to one of these two groups. The total duration of the study is 13 weeks: 1 baseline week and 12 intervention weeks. During the baseline week, the intervention and control group both use the app with limited functionality. Kata records their inhalations but does not provide inhalation training or feedback. This is to first assess how well patients are able to use their inhaler(s) without receiving support. After the first week, the intervention group starts using the app with full functionality for 12 weeks, which means that the app provides them with inhalation training and personalized feedback. The control group continues to use the app with limited functionality for 12 weeks, that means that they continue to use the app to record their inhalations but do not receive any inhalation training or feedback. This study will compare the patients in the intervention and control group, to find out the effect of using the Kata® inhalation app on the number of errors patients make when using their inhaler, therapy compliance, and health-related outcomes (asthma control, quality of life, and lung function).

Status (registry)
Completed
Study type
Interventional
Enrollment
146 (actual)
First submitted
23 Nov 2023
Start date
20 Dec 2023
Primary completion date
14 Jan 2025
Lead sponsor
VisionHealth GmbH
Diseases
Asthma
NCT number
NCT06178341

What you commit to

  • Study type: Interventional
  • Participants enrolled: 146
  • From 20 Dec 2023 to the primary completion date, 14 Jan 2025
  • 13 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Confirmed SARS-CoV-2 infection at screening.
    • Prior/Concomitant Therapy
  • Previous use of the Kata Inhalations-App.
    • Prior/Concurrent Clinical Study Experience
  • Use of any investigational drug or participation in any clinical study within 30 days prior to the expected date of first application of study intervention.
  • Previous randomization in this study.
    • Other Exclusions

Other illness

  • Medical Conditions
  • History or evidence of any clinically relevant and/or major disease that, in the opinion of the Investigator, would constitute a risk when taking part in the study or interfere with the interpretation of data.
  • Any other conditions or factors which in the opinion of the Investigator may interfere with study conduct.

Other

  • Subjects are excluded from the study if any of the following criteria apply:
  • Employee of VisionHealth, the study site, the Nuvisan Group, or other Contract Research Organization involved in the study.
  • Legal incapacity or limited legal capacity, or incarceration.
  • Inability to understand or communicate reliably with the Investigator or considered by the Investigator to be unable to or unlikely to co-operate with the protocol requirements, instructions, and study-related restrictions.

Who the study is looking for

  • A subject is eligible to be included in the study only if all of the following criteria apply:
  • Age
  • At least 18 years of age at the time of signing the informed consent.
    • Sex
  • Male or female.
    • Type of Subject and Disease Characteristics
  • Sufficient knowledge of the German language as assessed by the Investigator.
  • Capability to use a smartphone comfortably in the opinion of the Investigator: the subject uses a smartphone on a regular basis, and makes use of smartphone applications (i.e., uses the smartphone for more than calling and sending text messages).
  • Established diagnosis of asthma.
  • Regular use (i.e., at least once daily) of at least 1 of the following devices: metered-dose inhalers (MDIs), Respimat, NEXThaler, Ellipta, Easyhaler, Breezhaler and Turbohaler.
  • Stable disease (i.e., no exacerbation and/or change in treatment regimen) within the last 4 weeks prior to screening.
    • Informed Consent
  • Provision of written informed consent prior to any study specific procedure.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (13)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Herzzentrum des Universitätsklinikums Bonn
Coordinator of this site? Confirm its status
BonnGermanyUnknown status
Krankenhaus der Augustinerinnen
Coordinator of this site? Confirm its status
CologneGermanyUnknown status
MVZ Dachau
Coordinator of this site? Confirm its status
DachauGermanyUnknown status
Lungenzentrum Darmstadt
Coordinator of this site? Confirm its status
DarmstadtGermanyUnknown status
Lunge im Zentrum
Coordinator of this site? Confirm its status
ErlangenGermanyUnknown status
Studienzentrum Dr. Keller
Coordinator of this site? Confirm its status
Frankfurt am MainGermanyUnknown status
Thoraxklinik Heidelberg gGmbH
Coordinator of this site? Confirm its status
HeidelbergGermanyUnknown status
Marienkrankenhaus Kassel - Pneumologie
Coordinator of this site? Confirm its status
KasselGermanyUnknown status
Lungenärzte am Rundfunkplatz
Coordinator of this site? Confirm its status
MünchenGermanyUnknown status
Allgemeinmedizin Untermenzing
Coordinator of this site? Confirm its status
MünchenGermanyUnknown status
Facharztpraxis für Innere Medizin - Pneumologie - Allergologie
Coordinator of this site? Confirm its status
OberurselGermanyUnknown status
Pneumologische Praxis Wiesbaden
Coordinator of this site? Confirm its status
WiesbadenGermanyUnknown status
Lungenarztpraxis Dr. med. Maria Weber
Coordinator of this site? Confirm its status
WiesbadenGermanyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.